ADGRL4 Recombinant Monoclonal Antibody

ADGRL4, also known as ELTD1, belongs to the adhesion G protein-coupled receptor family and plays a significant role in angiogenesis and vascular development. This receptor has garnered considerable research interest due to its involvement in endothelial cell biology and its emerging relevance in tumor angiogenesis studies, making it a compelling target for investigators exploring signal transduction pathways and vascular biology.

This recombinant monoclonal antibody, clone 18A11, offers the reproducibility and consistency that demanding research protocols require. Because it is produced using recombinant technology with a defined sequence, researchers can expect reliable performance across experiments and between lots, eliminating the variability concerns often associated with traditional hybridoma-derived antibodies. The human IgG1 isotype format and affinity chromatography purification ensure high specificity for your target detection needs.

Validated for immunohistochemistry applications, this antibody has been successfully tested in paraffin-embedded human kidney tissue at dilutions ranging from 1:50 to 1:200. The validation protocol employed citrate buffer antigen retrieval at pH 6.0 under high pressure, followed by overnight incubation at 4°C, demonstrating clear detection using HRP-conjugated secondary antibody and DAB visualization. This established IHC protocol provides a solid foundation for researchers examining ADGRL4 expression patterns in human tissue samples. The antibody is also suitable for ELISA applications, offering flexibility for quantitative detection workflows.

Supplied in a liquid format containing 50% glycerol in PBS with Proclin 300 preservative, this antibody is ready for immediate use in your signal transduction research. Whether investigating ADGRL4's role in vascular development or exploring its expression in pathological contexts, this recombinant antibody delivers the consistency your research demands.